AU2019295769B2 - Amino acid compounds with unbranched linkers and methods of use - Google Patents
Amino acid compounds with unbranched linkers and methods of use Download PDFInfo
- Publication number
- AU2019295769B2 AU2019295769B2 AU2019295769A AU2019295769A AU2019295769B2 AU 2019295769 B2 AU2019295769 B2 AU 2019295769B2 AU 2019295769 A AU2019295769 A AU 2019295769A AU 2019295769 A AU2019295769 A AU 2019295769A AU 2019295769 B2 AU2019295769 B2 AU 2019295769B2
- Authority
- AU
- Australia
- Prior art keywords
- tetrahydro
- compound
- naphthyridin
- deuterium
- nonanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690939P | 2018-06-27 | 2018-06-27 | |
| US62/690,939 | 2018-06-27 | ||
| PCT/US2019/039624 WO2020006315A1 (en) | 2018-06-27 | 2019-06-27 | Amino acid compounds with unbranched linkers and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019295769A1 AU2019295769A1 (en) | 2021-02-11 |
| AU2019295769B2 true AU2019295769B2 (en) | 2024-05-23 |
Family
ID=68987528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019295769A Active AU2019295769B2 (en) | 2018-06-27 | 2019-06-27 | Amino acid compounds with unbranched linkers and methods of use |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11396506B2 (https=) |
| EP (1) | EP3813818A4 (https=) |
| JP (2) | JP7425757B2 (https=) |
| KR (1) | KR20210043561A (https=) |
| CN (1) | CN112689507B (https=) |
| AU (1) | AU2019295769B2 (https=) |
| BR (1) | BR112020026278A2 (https=) |
| CA (1) | CA3104682A1 (https=) |
| CL (1) | CL2020003382A1 (https=) |
| CR (1) | CR20210041A (https=) |
| CU (1) | CU24693B1 (https=) |
| DO (1) | DOP2020000255A (https=) |
| EA (1) | EA202190134A1 (https=) |
| EC (1) | ECSP21005655A (https=) |
| IL (2) | IL308960A (https=) |
| JO (1) | JOP20200330A1 (https=) |
| MX (1) | MX2020014086A (https=) |
| PE (1) | PE20210137A1 (https=) |
| PH (1) | PH12020552260A1 (https=) |
| SA (1) | SA520420897B1 (https=) |
| SG (1) | SG11202013027RA (https=) |
| TW (1) | TWI841573B (https=) |
| WO (1) | WO2020006315A1 (https=) |
| ZA (1) | ZA202100211B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11306084B2 (en) | 2016-12-29 | 2022-04-19 | Saint Louis University | Integrin antagonists |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| TWI776067B (zh) | 2018-06-29 | 2022-09-01 | 美商維托平面玻璃有限責任公司 | 可燒除保護性塗層 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| TW202135812A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
| US20230060422A1 (en) * | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| GB202209228D0 (en) | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US20020035127A1 (en) * | 1998-01-27 | 2002-03-21 | Celltech Therapeutis, Limited | Phenylalanine derivatives |
| US20090104116A1 (en) * | 2006-01-31 | 2009-04-23 | Jerini Ag | Compounds for the inhibition of integrins and use thereof |
| US20180093984A1 (en) * | 2016-09-07 | 2018-04-05 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010033248A (ko) * | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| US20080182842A1 (en) * | 2007-01-29 | 2008-07-31 | Astrazeneca Ab | L-alanine derivatives as a5beta1 antagonists |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| BR112017023432A2 (pt) * | 2015-04-30 | 2018-07-24 | Scifluor Life Sciences Inc | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo |
| US11192889B2 (en) | 2016-07-05 | 2021-12-07 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) * | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| WO2021097338A1 (en) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| MX2023012794A (es) | 2021-04-30 | 2023-12-15 | Pliant Therapeutics Inc | Regímenes de dosificación expandidos para inhibidores de integrina. |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| TW202329973A (zh) | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
-
2019
- 2019-06-26 TW TW108122460A patent/TWI841573B/zh active
- 2019-06-27 CA CA3104682A patent/CA3104682A1/en active Pending
- 2019-06-27 CR CR20210041A patent/CR20210041A/es unknown
- 2019-06-27 SG SG11202013027RA patent/SG11202013027RA/en unknown
- 2019-06-27 PE PE2020002165A patent/PE20210137A1/es unknown
- 2019-06-27 IL IL308960A patent/IL308960A/en unknown
- 2019-06-27 KR KR1020217002250A patent/KR20210043561A/ko not_active Withdrawn
- 2019-06-27 WO PCT/US2019/039624 patent/WO2020006315A1/en not_active Ceased
- 2019-06-27 CN CN201980050125.6A patent/CN112689507B/zh active Active
- 2019-06-27 BR BR112020026278-1A patent/BR112020026278A2/pt unknown
- 2019-06-27 MX MX2020014086A patent/MX2020014086A/es unknown
- 2019-06-27 CU CU2021000001A patent/CU24693B1/es unknown
- 2019-06-27 EA EA202190134A patent/EA202190134A1/ru unknown
- 2019-06-27 IL IL279717A patent/IL279717B2/en unknown
- 2019-06-27 US US16/455,490 patent/US11396506B2/en active Active
- 2019-06-27 AU AU2019295769A patent/AU2019295769B2/en active Active
- 2019-06-27 EP EP19826330.3A patent/EP3813818A4/en active Pending
- 2019-06-27 JO JOP/2020/0330A patent/JOP20200330A1/ar unknown
- 2019-06-27 JP JP2020572976A patent/JP7425757B2/ja active Active
-
2020
- 2020-12-23 DO DO2020000255A patent/DOP2020000255A/es unknown
- 2020-12-23 CL CL2020003382A patent/CL2020003382A1/es unknown
- 2020-12-23 PH PH12020552260A patent/PH12020552260A1/en unknown
- 2020-12-26 SA SA520420897A patent/SA520420897B1/ar unknown
-
2021
- 2021-01-12 ZA ZA2021/00211A patent/ZA202100211B/en unknown
- 2021-01-26 EC ECSENADI20215655A patent/ECSP21005655A/es unknown
-
2022
- 2022-02-23 US US17/679,002 patent/US11858931B2/en active Active
-
2023
- 2023-11-15 US US18/509,872 patent/US20240294520A1/en active Pending
-
2024
- 2024-01-19 JP JP2024006536A patent/JP2024055873A/ja not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US20020035127A1 (en) * | 1998-01-27 | 2002-03-21 | Celltech Therapeutis, Limited | Phenylalanine derivatives |
| US20090104116A1 (en) * | 2006-01-31 | 2009-04-23 | Jerini Ag | Compounds for the inhibition of integrins and use thereof |
| US20180093984A1 (en) * | 2016-09-07 | 2018-04-05 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019295769B2 (en) | Amino acid compounds with unbranched linkers and methods of use | |
| ES2972512T3 (es) | Compuestos de aminoácido y métodos de uso | |
| AU2020341681B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| US11952376B2 (en) | Substituted amino acids as integrin inhibitors | |
| JP7379467B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| ES3055608T3 (en) | Heterocyclic rip1 inhibitory compounds | |
| CA3200594A1 (en) | Imidazopyridazine derivatives as il-17 modulators | |
| WO2020061375A1 (en) | Antibacterial compounds | |
| ES2733505T3 (es) | Derivados de 6-morfolinil-2-pirazolil-9H-purina y su uso como inhibidores PI3K | |
| HK40049583A (en) | Amino acid compounds with unbranched linkers and methods of use | |
| BR122023025996A2 (pt) | Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |